
With April 1 as the starting point, Horizon Therapeutics expects to put a stop to the supply issues which have affected the company's new and highly popular launch Tepezza since December last year, which the firm states in a press release.
The firm's solution, as it turns out, is that it has received approval from the US Food and Drug Administration (FDA) to introduce a new production setup, which allows Horizon Therapeutics to produce more of the drug itself, rather than outsourcing this task to contractors.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Fruergaard leveraging experience from Danish partnerships in key roles in Brussels
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.